# US 2020/0390779 A1 · Imidazopyridine compounds and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390779 A1
- Document ID: US20200390779A1
- Status: Published application
- Kind: A1
- Application number: 17/005,238
- Filed: 2020-08-27
- Published: 2020-12-17
- Earliest claimed: 2013-01-31
- Assignees: Neomed Institute
- Applicants: Neomed Institute
- Inventors: Christophe BUON; Louis-David CANTIN; Yun-Jin HU; Xuehong LUO; Miroslaw Jerzy TOMASZEWSKI
- Web page: https://patentgrep.com/patent/US20200390779A1

## CPC

- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 11/14: Antitussive agents
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/10: of the bladder
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/24: Antidepressants
- A61P 25/32: Alcohol-abuse
- A61P 25/34: Tobacco-abuse
- A61P 25/36: Opioid-abuse
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- C07D 471/04: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

This invention generally relates to substituted imidazopyridine compounds, particularly substituted 4-(imidazo[1,2-a]pyridin-2-yl)benzamide compounds and salts thereof. This invention also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including, for example, treatment methods and medicament preparations), processes for making such a compound, and intermediates used in such processes.

## Claims

### Claim 1

A method for treating a disorder associated with P2X3 activity in an animal, wherein the disorder associated with P2X3 activity is selected from the group consisting of multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, endometriosis, depression, anxiety, a stress-related disorder, and drug addiction, and wherein the method comprises administering to the animal a therapeutically effective amount of a pharmaceutically active compound of Formula (I) or a salt thereof, wherein the compound of Formula (I) is:
R1 is selected from the group consisting of cyano, halogen, methyl, and ethyl;
R2 is selected from the group consisting of hydrogen, halogen, methyl, and ethyl;
R3 is selected from the group consisting of halogen, methyl, and ethyl;
R4 is selected from the group consisting of hydrogen, halogen, methyl, ethyl, and methoxy;
as to R5 and R6;
R5 and R6 are independently selected from the group consisting of hydrogen, C1-C6-alkyl, and hydroxy-C1-C6-alkyl; or
R5 and R6, together with the nitrogen to which they are both attached, form a 5- or 6-member heterocycloalkyl, wherein:
the heterocycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, and C1-C4-alkyl;
R7 and R8 are independently selected from the group consisting of hydrogen and C1-C4-alkyl;
R9 is selected from the group consisting of C1-C6-alkyl, C3-C6-cycloalkyl, C1-C6-alkyl-C3-C6-cycloalkyl, halo-C1-C6-alkyl, C1-C6-alkoxy, halo-C1-C6-alkoxy, and C1-C6-alkoxy-C1-C6-alkyl; and
X is selected from a bond, CH2, and O.

### Claim 2 (depends on 1)

The method of claim 1, wherein R1 is methyl and R2 is hydrogen.

### Claim 3 (depends on 1)

The method of claim 1, wherein R3 and R4 are fluoro.

### Claim 4 (depends on 1)

The method of claim 1, wherein X is O.

### Claim 5 (depends on 1)

The method of claim 1, wherein the compound corresponds in structure to:
and
R4 is selected from the group consisting of halogen, methyl, and ethyl.

### Claim 6 (depends on 1)

The method of claim 1, wherein R5 is hydrogen and R6 is C1-C6-alkyl.

### Claim 7 (depends on 1)

The method of claim 1, wherein R6 is methyl.

### Claim 8 (depends on 1)

The method of claim 1, wherein R7 and R8 are hydrogen.

### Claim 9 (depends on 1)

The method of claim 1, wherein R9 is C1-C6-alkoxy.

### Claim 10 (depends on 1)

The method of claim 1, wherein R9 is methoxy.

### Claim 11 (depends on 1)

The method of claim 1, wherein the compound corresponds in structure to:

### Claim 12 (depends on 1)

The method of claim 1, wherein the compound corresponds in structure to:

### Claim 13 (depends on 1)

The method of claim 1, wherein the compound corresponds in structure to:

### Claim 14 (depends on 1)

The method of claim 1, wherein the compound corresponds in structure to:

### Claim 15 (depends on 1)

The method of claim 1, wherein the animal is a mammal.

### Claim 16 (depends on 15)

The method of claim 15, wherein the mammal is a human.

### Claim 17 (depends on 1)

The method of claim 1, wherein the disorder associated with P2X3 activity is endometriosis.

### Claim 18 (depends on 13)

The method of claim 13, wherein the disorder associated with P2X3 activity is endometriosis.

### Claim 19 (depends on 14)

The method of claim 14, wherein the disorder associated with P2X3 activity is endometriosis.

### Claim 20 (depends on 1)

The method of claim 1, wherein the method further comprises administering a second pharmaceutically active compound.

### Claim 21 (depends on 13)

The method of claim 13, wherein the method further comprises administering a second pharmaceutically active compound.

### Claim 22 (depends on 14)

The method of claim 14, wherein the method further comprises administering a second pharmaceutically active compound.
